TrialsgrambetaRCTs are beautiful

CROWN

2020

Lorlatinib in Untreated ALK-Positive Advanced NSCLC

In 296 patients with untreated advanced ALK-positive NSCLC, lorlatinib improved progression-free survival and intracranial response compared with crizotinib.

Result

Efficacy: BICR-assessed PFSHR 0.28 (95% CI 0.19-0.41) · P < 0.001

Below 1 favours lorlatinib, above 1 favours crizotinib.

Event rates
Absolute difference
39 points
NNT
3

Absolute difference and NNT are derived from the event rates.

Also reported: Intracranial ORR 82% vs 23% in patients with measurable baseline brain mets.

Original publication
Subtopic
ALK-rearranged NSCLC
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
Shaw AT, et al. N Engl J Med. 2020;383(21):2018-2029; Solomon BJ, et al. J Clin Oncol. 2024;42(29):3400-3409.doi 10.1056/NEJMoa2027187

Discussion & critique

Largest PFS effect ever reported in 1L ALK+ NSCLC; intracranial activity is the new benchmark.